Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab

Mult Scler. 2013 Feb;19(2):241-4. doi: 10.1177/1352458512444915. Epub 2012 Apr 5.

Abstract

The magnetization transfer ratio reflects the integrity of tissue structure, including myelination and axonal density. Mean magnetization transfer ratio fell in 18 untreated patients with multiple sclerosis both in normal appearing grey (-0.25 pu/year, p < 0.001) and white matter (-0.12 pu/year, p = 0.004). Conversely, mean magnetization transfer ratio was stable in 20 alemtuzumab-treated patients (grey matter: -0.01 pu/year, p = 0.87; white matter: -0.02 pu/year, p = 0.51). The gradient difference in grey matter was 0.25 pu/year (p < 0.001) after age-adjustment. These data suggest that in multiple sclerosis alemtuzumab protects against tissue damage in normal-appearing grey matter, perhaps by preventing new lesion formation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age Factors
  • Age of Onset
  • Alemtuzumab
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Brain / pathology
  • Cohort Studies
  • Disability Evaluation
  • Disease Progression
  • Female
  • Humans
  • Image Processing, Computer-Assisted
  • Linear Models
  • Magnetic Resonance Imaging / methods*
  • Male
  • Multiple Sclerosis, Relapsing-Remitting / diagnosis*
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Multiple Sclerosis, Relapsing-Remitting / pathology
  • Sex Factors

Substances

  • Antibodies, Monoclonal, Humanized
  • Alemtuzumab